Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1984 Mar;14(2):127-34.
doi: 10.1007/BF02469803.

Immunosuppressive activity of sera from gastric cancer patients

Immunosuppressive activity of sera from gastric cancer patients

M Sakita et al. Jpn J Surg. 1984 Mar.

Abstract

Sera from 60 gastric cancer patients and 20 patients with benign gastric diseases and 8 healthy controls were tested for inhibitory effects on the humoral response to sheep erythrocytes (SRBC) by the plaque forming cell assay (PFC R.I.) using mouse spleen cells and on the phytohemagglutinin (PHA)-induced blastogenesis of normal mouse spleen cells (PHA S.R.). Gastric cancer patient sera showed a significantly lower PFC R.I. than did sera from benign gastric disease patients and from the healthy controls. However, there was no appreciable interstage difference in the degree of depression. The PHA-induced blastogenesis of normal spleen cells was also decreased in the presence of sera from cancer patients, as compared to that in the presence of sera from benign disease patients and from the healthy controls. The depression progressed with advancing stage of cancer. The PHA S.R. showed significant negative correlations with serum levels of IAP, IS, alpha 1-acid glycoprotein and alpha 1-antitrypsin, but there were no such correlations between PFC R.I. and these glycoproteins in serum. There was also no correlation between the values of the PHA S.R. and the PFC R.I. These results suggest that these two assays may depict immunosuppressive activities operating through entirely different mechanisms.

PubMed Disclaimer

References

    1. Adv Immunol. 1974;18:209-77 - PubMed
    1. Cancer Res. 1981 Aug;41(8):3244-52 - PubMed
    1. Br J Surg. 1973 Sep;60(9):745-9 - PubMed
    1. Br J Cancer. 1972 Dec;26(6):427-38 - PubMed
    1. Gan. 1979 Apr;70(2):245-8 - PubMed